Venture capital has poured nearly $18 billion into healthcare AI in a single year. The return on that investment, by most accounts, is a smorgasbord of pilots. Roughly 83% of health systems are running generative AI experiments—and only 5 to 10% of those ever reach enterprise-wide deployment. The rest die in procurement, drown in integration reviews, or launch in two departments and quietly stop expanding.
UCSF Health, Kleiner Perkins, and Doerr Capital don’t think that’s purely a technology problem. They’re betting that the technology is being built in the wrong place.
